Sangamo Therapeutics Shares Jump After FDA Discussion on Accelerated Approval Pathway for Fabry Disease Drug

By MarketWatch | Oct 22, 2024 at 10:20 AM EST

Sangamo Therapeutics' stock surged as FDA interaction paved the way for accelerated approval of ST-920 for Fabry disease. The company anticipates a biologics license application submission in 2025, three years ahead of previous estimates, without the need for additional clinical studies.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.